{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:56:40Z","timestamp":1759341400436},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1094,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1469-0691.2011.03680.x","type":"journal-article","created":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T16:58:10Z","timestamp":1316537890000},"page":"1769-1775","source":"Crossref","is-referenced-by-count":16,"title":["Viral infections associated with the clinical use of monoclonal antibodies"],"prefix":"10.1016","volume":"17","author":[{"given":"G.","family":"Gentile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2011.03680.x_bib1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor\u2010\u03b1 neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti\u2010tumor necrosis factor\u2010alpha therapy with infliximab for Crohn\u2019s disease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti\u2010TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta\u2010analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.gtc.2006.09.008","article-title":"Safety of infliximab and other biologic agents in the inflammatory bowel diseases","volume":"35","author":"Reddy","year":"2006","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis\u00a0B update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2008.02.001","article-title":"Management of viral hepatitis in hematologic malignancies","volume":"22","author":"Firpi","year":"2008","journal-title":"Blood Rev"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib7","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","article-title":"How I treat and monitor viral hepatitis\u00a0B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis\u00a0B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","author":"Manzano\u2010Alonso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"Clinical practice guidelines: management of chronic hepatitis\u00a0B","volume":"50","author":"EASL","year":"2009","journal-title":"J Hepatol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis\u00a0B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis\u00a0B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of the novo hepatitis\u00a0B infection in HBsAg\u2010negative patients undergoing cytotoxic therapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X","article-title":"Lamivudine in the treatment of hepatitis\u00a0B virus reactivation during cytotoxic chemotherapy","volume":"59","author":"Yeo","year":"1999","journal-title":"J Med Virol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis\u00a0B virus by cytotoxic T\u00a0lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/clinids\/18.2.194","article-title":"Serum levels of interleukin\u20101\u00a0alpha, interleukin\u20101\u00a0beta, interleukin\u20106, and tumor necrosis factor in patients with acute viral hepatitis","volume":"18","author":"Torre","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti\u2010tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab\u2010related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib20","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis\u00a0B virus reactivation in lymphoma patients with prior resolved hepatitis\u00a0B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.autrev.2009.08.006","article-title":"Incidence and nature of infectious disease in patients treated with anti\u2010TNF agents","volume":"9","author":"Raychaudhuri","year":"2009","journal-title":"Autoimm Rev"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e328338f6df","article-title":"The A,B,Cs of viral hepatitis in the biologic era","volume":"22","author":"Ferri","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib24","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in HCV\u2010infected patients with diffuse large B\u2010cell lymphoma treated with rituximab\u2010containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis\u00a0C virus (HCV) RNA in patients with HCV\u2010infected CD20\u2010positive B\u2010cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib26","doi-asserted-by":"crossref","first-page":"688A","DOI":"10.1182\/blood.V106.11.2447.2447","article-title":"Diffuse B\u2010large cell lymphomas (DBLCL) with hepatitis\u00a0C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R\u2010CHOP with antiviral therapy","volume":"106","author":"Musto","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib27","first-page":"1","article-title":"CDC Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation","volume":"49","year":"2000","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00002","article-title":"Guidelines for preventing opportunistic infections among HIV\u2010infected persons\u20142002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America","volume":"137","author":"Masur","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor\u2010\u03b1 inhibitors","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti\u2010TNF\u2010alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib31","first-page":"E3","article-title":"Recent development in new and old viral infections","volume":"9","author":"Gentile","year":"2005","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jmv.21779","article-title":"Prospective cytomegalovirus monitoring during first\u2010line chemotherapy in patients with acute leukemia","volume":"82","author":"Capria","year":"2010","journal-title":"J Med Virol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jcv.2008.06.002","article-title":"Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti\u2010TNF\u2010alpha therapy","volume":"43","author":"D\u2019Ovidio","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection","volume":"6","author":"Kim","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","article-title":"Tumor necrosis factor\u2010alpha blockade for the treatment of acute GVHD","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","article-title":"Rediscovering alemtuzumab: current and emerging therapeutic roles","volume":"144","author":"Gribben","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendation for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.10.77","article-title":"Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab","volume":"4","author":"Vallejo","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib40","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath\u20101H in delaying immune reconstitution","volume":"99","author":"Chakrabartti","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib41","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/leu.2009.146","article-title":"Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia","volume":"23","author":"Osteborg","year":"2009","journal-title":"Leukemia"},{"issue":"suppl 5","key":"10.1111\/j.1469-0691.2011.03680.x_bib42","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","article-title":"Strategies in the management of alemtuzumab\u2010related side effects","volume":"33","author":"Osterborg","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib43","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valaciclovir prophylaxis against cytomegalovirus reactivation in recipients of allogenic bone marrow transplantation","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":"Rituximab therapy increased post\u2010transplant cytomegalovirus complications in non\u2010Hodgkin lymphoma patients receiving autologous hematopoietic stem cell transplantation","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib45","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD\u201052 antibody","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib47","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1086\/597089","article-title":"Infectious complications of antilymphocyte therapies in solid organ transplantation","volume":"48","author":"Issa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein\u2013Barr virus\u2010related lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of the reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusion of donor leukocytes to treat Epstein\u2013Barr virus\u2010associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopolous","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib50","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty\u2010six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib51","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib52","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/TP.0b013e3181fa941b","article-title":"Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case\u2010controlled study","volume":"90","author":"Scemla","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib53","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2005-08-3213","article-title":"Severe huma herpesvirus\u20108 primary infection in a renal transplant patient successfully treated with anti\u2010CD20 monoclonal antibody","volume":"197","author":"Thaunat","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03680.x_bib54","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ibd.20131","article-title":"Infliximab and the risk of latent viruses reactivation in active Crohn\u2019s disease","volume":"13","author":"Lavagna","year":"2007","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14619194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14619194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:41:04Z","timestamp":1592995264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14619194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1198743X14619194"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03680.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}